This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Dendreon to Build $70 Million Plant Near Atlanta
The 160,000 square-foot facility could bring at least 300 jobs to Georgia.
Provenge Extends Life of Prostate Cancer Patients, Study Finds
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.